Human IL-6 ELISA kit is intended for measuring in vitro quantitative concentrations of interleukin-6 (IL-6) present in human serum, biological fluids, plasma (EDTA, citrate, heparin) and tissue homogenates. This assay has a minimum detection limit of 2.813 pg/ml.
Interleukin 6 (IL-6) which can also be called by many other names including interferon-beta 2 gene (IFNB2), hybridoma growth factor (HGF) and hepatocyte stimulating factor (HSF) and B-cell stimulation factor-2 (BSF-2). IL-6 is a multi-functional protein that important functions in immune responses, host defence, hematopoiesis and acute phase reactions. The proteins which are derived from this gene are known to be responsible for mediating the plasma protein response to tissue injury (called the acute-phase response) and regulating the growth and differentiation of both T and B cells. It is not only involved in the hepatic acute phase response but is also responsible for lipoprotein lipase activity, hepatic triglyceride secretion and adipose tissue metabolism.
The overproduction of interleukin 6 has been associated with a large spectrum of age-related conditions such as osteoporosis, arthritis, cardiovascular disease, certain cancers, type 2 diabetes, periodontal disease, functional decline and frailty. IL-6 is predicted to contain a four helix-bundle type tertiary structure that is common among other cytokines such as G-CSF, IL-11, MGF, OSM, CNTF, EPO, LIF, hGH and prolactin. The results of structure-function studies of IL-6 and the other four a-helix bundle cytokines indicates that the helix D regions (c-terminal) are mainly responsible for the binding to their respective receptors.
IL-6 is expressed by a number of different normal and transformed cells which can include vascular endothelial cells, monocytes/macrophages, T cells, B cells, astrocytes, osteoblasts, hepatocytes, mesangial cells, keratinocytes, fibroblasts, melanomas, glioblastomas, myelomas, carcinomas and sarcomas. Also, the production of interleukin-6 can be up-regulated by many signals such as antigenic or mitogenic stimulation, calcium ionophore, lipopolysaccharide, IL-1, IL-2, PDGF, TNF, IFN and viruses. Whereas, both IL-4 and IL-13 are known to inhibit IL-6 expression within monocytes. The many different activities of IL-6 suggest that this factor plays a vital role in the mediating the immune and inflammatory responses.
IL-6 ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- One 96-Well Plate: Pre-coated with anti-human IL-6 antibody.
- Standards: Concentrations 0, 4.688, 9.375, 18.75, 37.5, 75, 150, 300 pg/ml, made up from lyophilized recombinant human interleukin-6.
- Sample/Standard Dilution Buffer.
- Biotinylated-labelled IL-6 Antibody.
- Antibody Dilution Buffer.
- HRP-Streptavidin Conjugate (SABC).
- SABC Dilution Buffer.
- TMB Substrate.
- Wash Buffer (25x).
- Plate Sealer.
- Product Instructions.
The minimum detection sensitivity level of interleukin-6 (IL-6) using this human IL-6 ELISA kit was approximately 2.813 pg/ml. The dynamic range for this assay is 4.688 – 300 pg/ml.
– Interleukin-6 (IL-6): ELISA
– Specificity: Highly specific for IL-6, no cross reactivity or interference between IL-6 and analogues was detected.
– Recovery: Serum (90 – 100%), EDTA Plasma (86 – 101%), Heparin Plasma (86 – 100%).
– Linearity: Serum (93 – 105%), EDTA Plasma (84 – 100%), Heparin Plasma (81 – 99%).
– Precison Intra-Assay: CV < 8%.
– Precison Inter-Assay: CV < 10%.
– Stability: Less than 10%.
- Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance. Curr Pharm Des. (2016) 22 (5): 518-26. Review. Ghandadi M. and Sahebkar A.
- Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. (2016) 37 (9): 11553-11572. Review. Kumari N., et al.
- Gene of the month: Interleukin 6 (IL-6). J Clin Pathol. (2014) 67 (11): 932-7. Review. Ataie-Kachoie P., et al.
- Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. (2012) 33 (11): 571-7. Review. Rincon M.
- The biology behind interleukin-6 targeted interventions. Curr Opin Rheumatol. (2016) 28 (2): 152-60. Review. Liu X., et al.
- Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. (2014) 59 (1-3): 188-202. Review. Rosean T.R., et al.
- Full Name: Interleukin-6 (IL-6) ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Tissue Homogenates, Biological Fluids, Plasma (Citrate, Heparin, EDTA)
- Sensitivity: 2.813 pg/ml